BTIG raised the firm’s price target on Natera to $135 from $125 and keeps a Buy rating on the shares. The firm cites the company’s Q2 earnings beat and raised 2024 guidance, also noting that Natera’s rapid growth, strong IP, commercial team, publications, and first-mover advantage in solid tumor MRD makes it difficult to compete against, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA: